TSLP: The Epithelial Alarmin That Opens the Type 2 Cascade
Allergic disease is usually described from the immune side, through IgE, eosinophils and interleukins. The first event, however, happens in the epithelium. Barrier cells sense an allergen or a virus and release a signal before any immune cell has arrived. Thymic stromal lymphopoietin is the best-studied of those signals.
An Interleukin-7 Relative With a Different Job
TSLP is an interleukin-7-like cytokine, and its name records the assay that found it rather than its biology. It acts on antigen-presenting cells and supports the maturation of T cell populations, which is how it was first characterised.
It is produced mainly by non-haematopoietic cells: fibroblasts, epithelial cells, and various stromal or stromal-like cells. That origin separates it from the classical lymphocyte-derived cytokines and explains why the epithelium can start an immune response on its own.
The four conditions that dominate the allergy clinic are allergic rhinitis, asthma, atopic dermatitis and food allergy. The cells that initiate and sustain them include dendritic cells, mast cells, basophils, eosinophils and type 2 helper T cells.
Who Expresses It, and How Far Expression Spreads
Under normal conditions TSLP comes mostly from epithelium in skin, gut and lung. In inflammation the source list grows. Bronchial smooth muscle cells and lung fibroblasts begin to express it, and lesional skin from atopic dermatitis patients carries high TSLP.
That spread from epithelium into stroma is informative. It shows that the inflammatory microenvironment regulates TSLP expression directly, rather than merely responding to it. It also suggests an amplification loop in chronic disease, where a signal meant to be transient becomes a standing feature of the tissue.
The Three-Part Receptor
TSLP signals through a ternary complex. It binds the thymic stromal lymphopoietin receptor, CRLF2, together with the IL-7 receptor alpha chain. Assembly of all three components is required before intracellular signalling begins.
The shared IL-7Rα subunit has consequences. It lets TSLP cross-regulate with other members of the IL-7 family at the same receptor chain. TSLPR distribution limits which cells can respond, while the broad expression of IL-7Rα extends the potential reach into immune and non-immune compartments.
Downstream, the complex activates JAK2 and the STAT factors. The result is transcriptional reprogramming of the target cell, which for a dendritic cell means activation and a shift toward type 2 instruction.
The Chemokine Relay
The sequence from exposure to infiltration has four steps, and each is separable.
An allergen or a virus triggers mucosal epithelial cells or skin cells to produce TSLP. TSLP binds its receptor on immature dendritic cells and activates them. Activated dendritic cells secrete IL-8 and eotaxin-2, which recruit neutrophils and eosinophils, along with TARC and MDC, which recruit Th2 cells.
Many stimuli regulate TSLP expression: cellular, microbial and environmental. A large share of them are associated with allergic inflammation. The chain therefore has several entry points and one shared consequence, a type 2 microenvironment marked by Th2 cells and eosinophil infiltration.
Why the Upstream Node Is the Better Target
TSLP sits at the start of that chain, which makes it an attractive point of intervention. Blocking a downstream cytokine removes one arm. Blocking TSLP can remove several at once, because the dendritic cell that coordinates them never receives its instruction.
Monoclonal antibodies against TSLP have entered clinical development for severe asthma and atopic dermatitis, and early results support the approach. The same logic extends upward in the airway: TSLP also contributes to type 2 inflammation in chronic rhinosinusitis with nasal polyps.
The comparison with anti-IL-4, anti-IL-5 and anti-IL-13 therapy is a comparison of position, not of potency. A receptor-proximal blockade trades specificity for breadth, and breadth is what a multi-cytokine cascade rewards.
Figure 1. Where each biologic intercepts the cascade. Anti-TSLP acts upstream of mast cells and basophils, eosinophils and the IL-4/IL-13 axis, while the downstream antibodies each remove a single arm.
Diagram of the type 2 cascade showing anti-TSLP blocking upstream of IgE-driven mast cells and basophils, IL-5-driven eosinophils, and the IL-4/IL-13 axis, with anti-IgE, anti-IL-5, anti-IL-5R and anti-IL-4Rα antibodies acting further downstream
A Mutant That Binds but Cannot Signal Properly
Tool development follows the clinical interest. The R127A and R130A double mutant changes the interface through which TSLP engages its receptor. It is used to identify the residues that govern receptor binding and to test how those residues affect signal activation.
The His tag supports purification by immobilised metal affinity chromatography and allows detection or capture with an anti-His antibody. Neither modification changes the experiment: the mutant is a probe for the binding step, not a substitute for the wild-type ligand.
Typical uses are binding analysis against the TSLPR/IL-7Rα complex and studies of how mutant forms shift JAK2-STAT activation. The same reagent supports in vitro screening of TSLP-directed antibodies and mechanism work in asthma and atopic dermatitis models.
Product Information
| Cat. No. | Product Name | Format | Purchase |
|---|---|---|---|
| UA040105 | TSLP (R127A, R130A) His Tag Protein, Human | Double mutant, His tag | |
| UA040102 | TSLP Protein, Human (For Cell Culture) | Cell culture grade | |
| UA010907 | TSLP R Fc Chimera Protein, Human | Receptor Fc chimera |
What to Fix Before the First Well
Three variables decide whether a TSLP binding experiment is interpretable. The receptor construct must be the same across arms, because a monomeric TSLPR behaves differently from the ternary complex. The mutant and wild-type ligands must be quantified by the same method, ideally by absorbance at 280 nm with a calculated extinction coefficient.
The third variable is the readout itself. Binding affinity and signalling potency are not interchangeable. A mutant that loses affinity usually loses potency. A mutant that keeps affinity and loses potency is the more interesting result, and only a paired assay will find it.
A fourth variable is less obvious and more expensive. The two ligands have to be handled identically after reconstitution: same buffer, same aliquot size, same freeze-thaw count. A wild-type protein thawed four times is not a fair comparator for a mutant thawed once. That difference will surface as a difference in potency.
That pairing is the practical reason to keep both a wild-type ligand and the double mutant on the shelf. One establishes the baseline; the other asks what the interface is doing.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.